Nanovi A/S is a medical device company specialized in the development and commercialization of innovative liquid fiducial markers. Our corporate commitment is to enable high-precision cancer treatments for better outcomes and higher quality of life for patients and to make healthcare more cost-efficient on a global scale.
”I founded Nanovi on a vision. A vision of substantially improving the treatment of cancer patients receiving radiation therapy and/or surgery via increased procedure precision. In both fields, technology advancements over past decades have made image-guided procedures available for better therapeutic outcome. However, to leverage the full potential of image-guided therapy there is a need for flexible fiducial markers to enable optimal target visualization across cancer types. Building on my expertise in biomaterial compositions for medical applications, we invented the carbo-gel technology platform as the basis for the development of novel liquid fiducial markers with unique features for accurate target marking to support high-precision radiotherapy and surgery.”
Thomas L. Andresen, Founder